Understanding and Optimizing Bone Health in Breast Cancer

References

• Bussard KM, Gay CV, Mastro AM. The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev 2008;27:41-55
   PubMed Web of Science ®Google Scholar
• Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-176
   PubMed Web of Science ®Google Scholar
• Saad F, Adachi JD, Brown JP, et al. Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 2008;26:5465-76
   PubMed Web of Science ®Google Scholar
• Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93
   PubMed Web of Science ®Google Scholar
• Clines GA, Guise TA. Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med 2008;10:e7
   PubMedGoogle Scholar
• Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 1989;8:98-101
   PubMed Web of Science ®Google Scholar
• Steeg PS, Theodorescu D. Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol 2008;5:206-19
   PubMedGoogle Scholar
• Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64
   PubMed Web of Science ®Google Scholar
• Zhao Y, Bachelier R, Treilleux I, et al. Tumor αvβ3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res 2007;67:5821-30
   PubMed Web of Science ®Google Scholar
• Ye L, Kynaston HG, Jiang WG. Bone metastasis in prostate cancer: molecular and cellular mechanisms (Review). Int J Mol Med 2007;20:103-11
   PubMed Web of Science ®Google Scholar
• Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76
   PubMed Web of Science ®Google Scholar
• Powell GJ, Southby J, Danks JA, et al. Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res 1991;51:3059-61
   PubMed Web of Science ®Google Scholar
• Yin JJ, Selander K, Chirgwin JM, et al. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999;103:197-206
   PubMed Web of Science ®Google Scholar
• Kakonen SM, Selander KS, Chirgwin JM, et al. Transforming growth factor-β stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 2002;277:24571-8
   PubMed Web of Science ®Google Scholar
• Grano M, Mori G, Minielli V, et al. Breast cancer cell line MDA-231 stimulates osteoclastogenesis and bone resorption in human osteoclasts. Biochem Biophys Res Commun 2000;270:1097-100
   PubMed Web of Science ®Google Scholar
• Wani MR, Fuller K, Kim NS, et al. Prostaglandin E2 cooperates with TRANCE in osteoclast induction from hemopoietic precursors: synergistic activation of differentiation, cell spreading, and fusion. Endocrinology 1999;140:1927-35
   PubMed Web of Science ®Google Scholar
• Kakonen S-M, Mundy GR. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 2003;97:834-9
   PubMed Web of Science ®Google Scholar
• Roelofs AJ, Thompson K, Gordon S. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006;12:6222-30s
   PubMed Web of Science ®Google Scholar
• Denosumab [prescribing information]. Thousand Oaks, CA: Amgen Inc., 2010
   Google Scholar
• Gligorov J, Pritchard K, Goss P. Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis. Breast 2007;16(Suppl 3):S1-9
   PubMedGoogle Scholar
• Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007;25:486-92
   PubMed Web of Science ®Google Scholar
• Coombes RC, Kilburn LS, Snowdon CF, et al. Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment: a randomised controlled trial. Lancet 2007;369:559-70
   PubMed Web of Science ®Google Scholar
• Forbes JF, Cuzick J, Buzdar A, et al. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45-53
   PubMed Web of Science ®Google Scholar
• Mouridsen HT, Giobbie-Hurder A, Mauriac L, et al. BIG 1-98 Collaborative and the International Breast Cancer Study Group. BIG 1-98: a randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Cancer Res 2009;69(2 Suppl):Abstract 13
   Google Scholar
• Brufsky AM. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. Oncologist 2008;13:187-95
   PubMed Web of Science ®Google Scholar
• Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001;19:3306-11
   PubMed Web of Science ®Google Scholar
• Vehmanen L, Saarto T, Elomaa I, et al. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer 2001;37:2373-8
   PubMed Web of Science ®Google Scholar
• Saarto T, Blomqvist C, Valimaki M, et al. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 1997;15:1341-7
   PubMed Web of Science ®Google Scholar
• Delmas PD, Balena R, Confravreux E, et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997;15:955-62
   PubMed Web of Science ®Google Scholar
• Brufsky A, Harker G, Beck JT, et al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 5-year final follow-up. Cancer Res 2009;69(24 Suppl):Abstract 4083
   Google Scholar
• Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010 May 5. [Epub ahead of print]
   Google Scholar
• Lester J, Dodwell D, Purohit OP. Use of monthly oral ibandronate to prevent anastrozole-induced bone loss during adjuvant treatment for breast cancer: two-year results from the ARIBON study. J Clin Oncol 2008;26(May 20 Suppl):Abstract 554
   Google Scholar
• Van Poznak C, Hannon RA, Clack G, et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 2010;28:967-75
   PubMed Web of Science ®Google Scholar
• Singh S, Cuzick J, Edwards R, et al. Effect of anastrozole on bone mineral density after one year of treatment: results from bone sub-study of the International Breast Cancer Intervention Study (IBIS-II). Breast Cancer Res Treat 2007;106(1 Suppl):Abstract 28
   Google Scholar
• Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Austrian Breast and Colorectal Cancer Study Group. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008;9:840-9
   PubMed Web of Science ®Google Scholar
• Gnant M, Mlineritsch B, Stoeger H, et al. Mature results from ABCSG-12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer. J Clin Oncol 2010;28:Abstract 533
   Google Scholar
• Hershman DL, McMahon DJ, Crew KD, et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2008;26:4739-45
   PubMed Web of Science ®Google Scholar
• Shapiro CL, Halabi S, Gibson G, et al. Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): first results from CALGB trial 7980. J Clin Oncol 2008;26(15S):Abstract 512
   Google Scholar
• Cummings SR, San Martin J, McClung MR, et al. FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65
   PubMed Web of Science ®Google Scholar
• Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008;26:4875-82
   PubMed Web of Science ®Google Scholar
• Ellis GK, Bone HG, Chlebowski R, et al. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat 2009;118:81-7
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. A randomised, double-blind, placebo-controlled, multi-centre phase 3 study to determine the treatment effect of denosumab in subjects with non-metastatic breast cancer receiving aromatase inhibitor therapy. Clinicaltrials.gov web site. Available at: http://clinicaltrials.gov/ct2/show/NCT00556374. Accessed August 6, 2010
   Google Scholar
• National Institutes of Health. A randomised, double-blind, placebo-controlled study to evaluate AMG 162 in the treatment of bone loss in subjects undergoing aromatase inhibitor therapy for non-metastatic breast cancer. ClinicalTrials.gov Web site. Available at: http://clinicaltrials.gov/ct2/show/NCT00089661. Accessed August 6, 2010
   Google Scholar
• Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-57
   PubMed Web of Science ®Google Scholar
• Paterson AH. Evaluating bone mass and bone quality in patients with breast cancer. Clin Breast Cancer 2005;(5 Suppl):S41-5
   PubMedGoogle Scholar
• National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Accessed at: http://www.nof.org/sites/default/files/pdfs/NOF_ClinicianGuide2009_v7.pdf (Accessed: October 14, 2010)
   Google Scholar
• Paterson AHG, Powles TJ, Kanis JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:59-65
   PubMed Web of Science ®Google Scholar
• Kristensen B, Ejlertsen B, Groenvold M, et al. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 1999;246:67-74
   PubMed Web of Science ®Google Scholar
• Tubiana-Hulin M, Beuzeboc P, Mauriac L, et al. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases]. Bull Cancer 2001;88:701-7
   PubMed Web of Science ®Google Scholar
• Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998;339:357-63
   PubMed Web of Science ®Google Scholar
• Glover D, Lipton A, Keller A, et al. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer: a dose-seeking study. Cancer 1994;74:2949-55
   PubMed Web of Science ®Google Scholar
• Coleman RE, Woll PJ, Miles M, et al. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Br J Cancer 1988;58:621-5
   PubMed Web of Science ®Google Scholar
• Morton AR, Cantrill JA, Pillai GV, et al. Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. BMJ 1988;297:772-3
   PubMed Web of Science ®Google Scholar
• Burckhardt P, Thiebaud D, Perey L, et al. Treatment of tumor-induced osteolysis by APD. Recent Results Cancer Res 1989;116:54-66
   PubMedGoogle Scholar
• Conte PF, Latreille J, Mauriac L, et al. The Aredia Multinational Cooperative Group. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. J Clin Oncol 1996;14:2552-9
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Theriault RL, Lipton A, et al. Protocol 19 Aredia Breast Cancer Study Group. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 1998;16:2038-44
   PubMed Web of Science ®Google Scholar
• Theriault RL, Lipton A, Hortobagyi GN, et al. Protocol 18 Aredia Breast Cancer Study Group. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 1999;17:846-54
   PubMed Web of Science ®Google Scholar
• Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082-90
   PubMed Web of Science ®Google Scholar
• Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003;14:1399-405
   PubMed Web of Science ®Google Scholar
• Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004;90:1133-7
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon DH, Dugan W Jr, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004;100:36-43
   PubMed Web of Science ®Google Scholar
• Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314-21
   PubMed Web of Science ®Google Scholar
• Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-Κβ ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12:1221-8
   PubMed Web of Science ®Google Scholar
• Lipton A, Steger GG, Figueroa J, et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res 2008;14:6690-6
   PubMed Web of Science ®Google Scholar
• Gralow J, Lipton A, Fizazi K, et al. Effects of denosumab treatment in breast cancer patients with bone metastases and elevated bone resorption levels after therapy with intravenous bisphosphonates: results of a phase 2 randomized trial. Cancer Res 2008;69(Suppl 15s):Abstract 1155
   Google Scholar
• Stopeck A, de Boer R, Fujiwara Y, et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal-related events in breast cancer patients with bone metastases. Cancer Res 2009;69(24 Suppl):Abstract 22
   Google Scholar
• Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008;34:453-75
   PubMed Web of Science ®Google Scholar
• Diel IJ, Jaschke A, Solomayer EF, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 2008;19:2007-11
   PubMed Web of Science ®Google Scholar
• Powles T, Paterson S, Kanis JA, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002;20:3219-24
   PubMed Web of Science ®Google Scholar
• Powles T, Paterson A, McCloskey E, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006;8:R13
   PubMed Web of Science ®Google Scholar
• Saarto T, Blomqvist C, Virkkunen P, et al. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001;19:10-7
   PubMed Web of Science ®Google Scholar
• Saarto T, Vehmanen L, Virkkunen P, et al. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004;43:650-6
   PubMed Web of Science ®Google Scholar
• Ha TC, Li H. Meta-analysis of clodronate and breast cancer survival. Br J Cancer 2007;96:1796-801
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. A clinical trial comparing adjuvant clodronate therapy vs. placebo in early-stage breast cancer patients receiving systematic chemotherapy and/or hormonal therapy or no therapy. Clinicaltrials.gov web site. Available at: http://clinicaltrials.gov/ct2/show/ NCT00009945. Accessed August 6, 2010
   Google Scholar
• van Holten-Verzantvoort AT, Hermans J, Beex LV, et al. Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients? Eur J Cancer 1996;32A:450-4
   PubMed Web of Science ®Google Scholar
• Kokufu I, Kohno N, Takao S, et al. Adjuvant pamidronate (PMT) therapy for the prevention of bone metastasis in breast cancer (BC) patients (pts) with four or more positive nodes. J Clin Oncol 2004;22:Abstract 530
   Google Scholar
• Jung J, Hwang G, Lee Y, et al. Pamidronate as adjuvant treatment for prevention of bone metastasis in breast cancer. J Clin Oncol 2005;23:Abstract 888
   Google Scholar
• Kristensen B, Ejlertsen B, Mouridsen HT, et al. Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol 2008;47:740-6
   PubMed Web of Science ®Google Scholar
• Rack B, Juckstock J, Genss EM, et al. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res 2010;30:1807-13
   PubMed Web of Science ®Google Scholar
• Lin A, Park J, Melisko M, et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and occult tumor cells in bone marrow. Breast Cancer Res Treat 2007;106(Suppl 1):Abstract 510
   Google Scholar
• Aft R, Naughton M, Trinkaus K, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010;11:421-8
   PubMed Web of Science ®Google Scholar
• Coleman R, Bundred N, De Boer R, et al. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. Cancer Res 2009;69(24 Suppl):Abstract 4082
   Google Scholar
• Chlebowski R, Chen Z, Cauley J, et al. Oral bisphosphonate and breast cancer: prospective results from the Women's Health Initiative (WHI). Cancer Res 2009;69(24 Suppl):Abstract 21
   Google Scholar
• Rennert G, Pinchev M, Rennert HS. Use of bisphosphonates and risk of postmenopausal breast cancer. Cancer Res 2009;69(24 Suppl):Abstract 27
   Google Scholar
• Coleman RE, Winter MC, Cameron D, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010;102:1099-105
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. A randomized, multicenter, open phase III study comparing the postoperative use of zoledronic acid versus no treatment in patients with histological tumor residuals after preoperative anthracycline and taxane containing chemotherapy for primary breast cancer. Clinicaltrials.gov web site Available at: http://clinicaltrials.gov/ct2/show/NCT00512993. Accessed August 6, 2010
   Google Scholar
• National Institutes of Health. Phase III trial of bisphosphonates as adjuvant therapy for primary breast cancer. Clinicaltrials.gov web site. Available at: http://clinicaltrials.gov/ct2/show/NCT00127205. Accessed August 22, 2010
   Google Scholar
• National Institutes of Health. A randomised phase II feasibility study investigating the biological effects of the addition of zoledronic acid to neoadjuvant combination chemotherapy on invasive breast cancer. Clinicaltrials.gov web site. Available at: http://clinicaltrials.gov/ct2/show/NCT00525759. Accessed August 22, 2010
   Google Scholar
• Sordillo EM, Pearse RN. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. Cancer 2003;97:802-12
   PubMed Web of Science ®Google Scholar
• Canon JR, Roudier M, Bryant R, et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 2008;25:119-29
   PubMed Web of Science ®Google Scholar
• Jacob A, Branstetter D, Jones J, et al. A RANKL inhibitor but not a bisphosphonate, zoledronic acid, reduces mammary tumor formation in a carcinogen- and hormone-dependent mouse model. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Abstract LB-156
   Google Scholar
• Zometa [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2010
   Google Scholar
• Ruggiero S, Gralow J, Marx R, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Practice 2006;2:7-14
   PubMedGoogle Scholar